Mark Pollack to Time Factors
This is a "connection" page, showing publications Mark Pollack has written about Time Factors.
Connection Strength
0.280
-
Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. J Psychiatr Res. 2008 Oct; 42(14):1176-84.
Score: 0.058
-
A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl). 2007 Oct; 194(2):233-42.
Score: 0.055
-
Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol. 2003 Sep; 17(3):276-82.
Score: 0.042
-
A novel cognitive-behavioral approach for treatment-resistant drug dependence. J Subst Abuse Treat. 2002 Dec; 23(4):335-42.
Score: 0.040
-
Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. J Clin Psychopharmacol. 1993 Aug; 13(4):257-63.
Score: 0.021
-
Methadone maintenance improves cognitive performance after two months of treatment. Exp Clin Psychopharmacol. 2006 May; 14(2):157-64.
Score: 0.013
-
Baseline predictors of serious adverse events at one year among patients with bipolar disorder in STEP-BD. Psychiatr Serv. 2005 Dec; 56(12):1541-8.
Score: 0.012
-
Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl). 2005 Jan; 177(3):280-8.
Score: 0.011
-
WCA Recommendations for the long-term treatment of posttraumatic stress disorder. CNS Spectr. 2003 Aug; 8(8 Suppl 1):31-9.
Score: 0.011
-
WCA recommendations for the long-term treatment of social phobia. CNS Spectr. 2003 Aug; 8(8 Suppl 1):40-52.
Score: 0.011
-
Pattern of placebo response in panic disorder. Psychopharmacol Bull. 1995; 31(2):273-8.
Score: 0.006